Market Overview:
The global inflammatory bowel disease drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of inflammatory bowel diseases, rising awareness about these diseases, and technological advancements in the field of drug development. The global inflammatory bowel disease drugs market is segmented on the basis of type into ulcerative colitis, Crohn’s disease, indeterminate colitis, and others. On the basis of application, it is segmented into amino-salicylates, antibiotics, corticosteroids, immunomodulators,, biologics,, and others. Geographically it is segmented into North America,, Latin America,, Europe,,,, Asia Pacific,,,,and Middle East & Africa,. The North American region dominates this market followed by Europe due to high incidence rates for IBD in these regions. However,.
Product Definition:
Inflammatory bowel disease drugs are used to treat the symptoms of inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. These drugs can help to reduce inflammation in the intestine, which can help to improve symptoms such as diarrhea, abdominal pain, and bleeding.
Ulcerative Colitis:
Ulcerative colitis is a type of Inflammatory Bowel Disease (IBD) that causes sores or ulcers in the innermost part of the colon and rectum. People with ulcerative colitis may also experience diarrhea, abdominal pain, loss of appetite, nausea and/or vomiting.
Crohns Disease:
Crohn's disease is a chronic, incurable, and often fatal disorder of the digestive system. It was first described in the U.S. by Dr. Hans Christian Andersen in 1847 as an intestinal inflammation resulting from a hypersensitive immune response to some dietary factors or irritants located within the small intestine (1).
The disease has been known by different names over time; however, it received its current name Crohn’s disease after Dr.
Application Insights:
The other application segment includes anti-inflammatory drugs that are not related to IBD. These drugs include analgesics, anthelmintics, antacids and gastrointestinal protectants. The antibiotics segment dominated the global inflammatory bowel disease (IBD) drug market in 2017 owing to increasing prevalence of Inflammatory Bowel Disease (IBD) coupled with the usage of broad spectrum antibiotics for treatment purposes.
Infectious diseases accounted for a significant share in the global healthcare spending and this trend is expected to continue over the forecast period as various countries continue investing in research & development activities for finding effective solutions against infectious diseases such as HIV/AIDS, tuberculosis etc. This factor is anticipated to fuel demand over the forecast period thereby supporting revenue growth during future years.
Regional Analysis:
North America dominated the global inflammatory bowel disease drugs market in 2017. This can be attributed to favorable healthcare infrastructure, high awareness levels coupled with the presence of key manufacturers. Moreover, increasing prevalence of IBD is also expected to contribute towards its growth over the forecast period.
Growth Factors:
- Increasing incidence of inflammatory bowel diseases (IBD) across the globe.
- Growing awareness about IBD and its treatment options among patients and healthcare professionals.
- Rising demand for novel and targeted therapies for the treatment of IBD.
- increasing research funding for the development of new drugs for the treatment of IBDs
Scope Of The Report
Report Attributes
Report Details
Report Title
Inflammatory Bowel Disease Drugs Market Research Report
By Type
Ulcerative Colitis, Crohns Disease, Indeterminate Colitis, Others
By Application
Amino-salicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Others
By Companies
Abbott Laboratories, Biocon Ltd, Roche, Johnson and Johnson, Mylan Pharmaceuticals, Novartis AG, Pfizer, Quest Medical, Sanofi, Takeda Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
250
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Inflammatory Bowel Disease Drugs Market Report Segments:
The global Inflammatory Bowel Disease Drugs market is segmented on the basis of:
Types
Ulcerative Colitis, Crohns Disease, Indeterminate Colitis, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Amino-salicylates, Antibiotics, Corticosteroids, Immunomodulators, Biologics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Biocon Ltd
- Roche
- Johnson and Johnson
- Mylan Pharmaceuticals
- Novartis AG
- Pfizer
- Quest Medical
- Sanofi
- Takeda Pharmaceutical
Highlights of The Inflammatory Bowel Disease Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ulcerative Colitis
- Crohns Disease
- Indeterminate Colitis
- Others
- By Application:
- Amino-salicylates
- Antibiotics
- Corticosteroids
- Immunomodulators
- Biologics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Inflammatory Bowel Disease Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Inflammatory bowel disease drugs are medications used to treat Crohn's disease and ulcerative colitis. These drugs help to reduce inflammation in the intestines, which can lead to better bowel function and reduced symptoms.
Some of the major players in the inflammatory bowel disease drugs market are Abbott Laboratories, Biocon Ltd, Roche, Johnson and Johnson, Mylan Pharmaceuticals, Novartis AG, Pfizer, Quest Medical, Sanofi, Takeda Pharmaceutical.
The inflammatory bowel disease drugs market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Inflammatory Bowel Disease Drugs Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Inflammatory Bowel Disease Drugs Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Inflammatory Bowel Disease Drugs Market - Supply Chain
4.5. Global Inflammatory Bowel Disease Drugs Market Forecast
4.5.1. Inflammatory Bowel Disease Drugs Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Inflammatory Bowel Disease Drugs Market Size (000 Units) and Y-o-Y Growth
4.5.3. Inflammatory Bowel Disease Drugs Market Absolute $ Opportunity
5. Global Inflammatory Bowel Disease Drugs Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Type
5.3.1. Ulcerative Colitis
5.3.2. Crohns Disease
5.3.3. Indeterminate Colitis
5.3.4. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Inflammatory Bowel Disease Drugs Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
6.3.1. Amino-salicylates
6.3.2. Antibiotics
6.3.3. Corticosteroids
6.3.4. Immunomodulators
6.3.5. Biologics
6.3.6. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Inflammatory Bowel Disease Drugs Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Inflammatory Bowel Disease Drugs Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Inflammatory Bowel Disease Drugs Demand Share Forecast, 2019-2026
9. North America Inflammatory Bowel Disease Drugs Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
9.4.1. Amino-salicylates
9.4.2. Antibiotics
9.4.3. Corticosteroids
9.4.4. Immunomodulators
9.4.5. Biologics
9.4.6. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Type
9.7.1. Ulcerative Colitis
9.7.2. Crohns Disease
9.7.3. Indeterminate Colitis
9.7.4. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Inflammatory Bowel Disease Drugs Demand Share Forecast, 2019-2026
10. Latin America Inflammatory Bowel Disease Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
10.4.1. Amino-salicylates
10.4.2. Antibiotics
10.4.3. Corticosteroids
10.4.4. Immunomodulators
10.4.5. Biologics
10.4.6. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Type
10.7.1. Ulcerative Colitis
10.7.2. Crohns Disease
10.7.3. Indeterminate Colitis
10.7.4. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Inflammatory Bowel Disease Drugs Demand Share Forecast, 2019-2026
11. Europe Inflammatory Bowel Disease Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
11.4.1. Amino-salicylates
11.4.2. Antibiotics
11.4.3. Corticosteroids
11.4.4. Immunomodulators
11.4.5. Biologics
11.4.6. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Inflammatory Bowel Disease Drugs Market Size and Volume Forecastby Type
11.7.1. Ulcerative Colitis
11.7.2. Crohns Disease
11.7.3. Indeterminate Colitis
11.7.4. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Inflammatory Bowel Disease Drugs Demand Share, 2019-2026
12. Asia Pacific Inflammatory Bowel Disease Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
12.4.1. Amino-salicylates
12.4.2. Antibiotics
12.4.3. Corticosteroids
12.4.4. Immunomodulators
12.4.5. Biologics
12.4.6. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Type
12.7.1. Ulcerative Colitis
12.7.2. Crohns Disease
12.7.3. Indeterminate Colitis
12.7.4. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Inflammatory Bowel Disease Drugs Demand Share, 2019-2026
13. Middle East & Africa Inflammatory Bowel Disease Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Application
13.4.1. Amino-salicylates
13.4.2. Antibiotics
13.4.3. Corticosteroids
13.4.4. Immunomodulators
13.4.5. Biologics
13.4.6. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Inflammatory Bowel Disease Drugs Market Size and Volume Forecast by Type
13.7.1. Ulcerative Colitis
13.7.2. Crohns Disease
13.7.3. Indeterminate Colitis
13.7.4. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Inflammatory Bowel Disease Drugs Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Inflammatory Bowel Disease Drugs Market: Market Share Analysis
14.2. Inflammatory Bowel Disease Drugs Distributors and Customers
14.3. Inflammatory Bowel Disease Drugs Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott Laboratories
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biocon Ltd
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Roche
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Johnson and Johnson
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Mylan Pharmaceuticals
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Novartis AG
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Quest Medical
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Sanofi
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Takeda Pharmaceutical
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
